Numerai GP LLC Purchases 70,191 Shares of Progyny, Inc. (NASDAQ:PGNY)

Numerai GP LLC boosted its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 117.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,883 shares of the company's stock after buying an additional 70,191 shares during the quarter. Numerai GP LLC owned approximately 0.15% of Progyny worth $2,240,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Leibman Financial Services Inc. boosted its stake in shares of Progyny by 100.7% during the fourth quarter. Leibman Financial Services Inc. now owns 63,509 shares of the company's stock valued at $1,096,000 after purchasing an additional 31,872 shares during the period. Fort Washington Investment Advisors Inc. OH boosted its stake in shares of Progyny by 90.1% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock valued at $25,319,000 after purchasing an additional 695,740 shares during the period. Clear Harbor Asset Management LLC purchased a new stake in shares of Progyny during the fourth quarter valued at approximately $989,000. Barclays PLC boosted its stake in shares of Progyny by 530.4% during the third quarter. Barclays PLC now owns 706,157 shares of the company's stock valued at $11,835,000 after purchasing an additional 594,140 shares during the period. Finally, Baillie Gifford & Co. boosted its stake in shares of Progyny by 52.2% during the fourth quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company's stock valued at $22,989,000 after purchasing an additional 456,853 shares during the period. Hedge funds and other institutional investors own 94.93% of the company's stock.

Progyny Price Performance

Shares of NASDAQ:PGNY traded down $1.01 during mid-day trading on Monday, reaching $21.29. 449,946 shares of the company traded hands, compared to its average volume of 1,710,167. The company's 50 day moving average price is $22.08 and its 200-day moving average price is $19.79. The firm has a market cap of $1.82 billion, a PE ratio of 36.77, a PEG ratio of 2.39 and a beta of 1.37. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). The company had revenue of $324.04 million for the quarter, compared to the consensus estimate of $307.86 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company's revenue was up 16.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.17 earnings per share. On average, research analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on PGNY shares. BTIG Research raised Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective for the company in a research note on Monday, March 31st. Bank of America upped their target price on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. upped their target price on Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Finally, Canaccord Genuity Group decreased their target price on Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a report on Monday, May 12th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $23.45.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.